Clinical Trials

Overview

About this study

This study is being done to determine the long-term response of patients with Lambert-Eaton Myasthenic Syndrome (LEMS) to the investigational drug [not yet approved by the Food and Drug Administration (FDA)] 3, 4-DAP. 3, 4-DAP increases the communication between the nerve and muscle by increasing the release of an important compound in this process, acetylcholine. This drug has been shown in studies done at Mayo and elsewhere to benefit patients with LEMS as well as some patients with congenital myasthenic syndromes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information